Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients

Table 1 Clinical characteristics of patients

Characteristic	n (%)
Total	90 (100.0)
Gender (M/F)	59 (65.6)/31 (34.4)
Median age (yr)	48 (range: 16-71)
Underlying disease
Multiple myeloma	46 (51.1)
Hodgkin’s lymphoma	23 (25.6)
Non-Hodgkin’s lymphoma	15 (4.4)
Acute myeloblastic leukemia	4 (4.4)
Acute lymphoblastic leukemia	1 (1.1)
Primitive neuroectodermal tumor	1 (1.1)
Conditioning regimen
Melphalan	47 (52.2)
BEAM	35 (38.9)
Busulfex-Cy	4 (4.4)
Busulfex-Melphalan	1 (1.1)
TBI-Cy-Thiotepa	1 (1.1)
Thiotepa-Cy-Bu	1 (1.1)
Z-BEAM	1 (1.1)

BEAM: The combination of Carmustine (BCNU), Etoposide, Cytarabine (Ara-C) and Melphalan; Z-BEAM: The combination of Ybritumomab Tiuxetan (Zevalin^®), Carmustine (BCNU), Etoposide, Cytarabine (Ara-C) and Melphalan; Cy: Cyclophosphamide; TBI: Total body irradiation.

Table 2 Pretransplant HBV serologic results and HBV-related events after transplantation n (%)

Pretransplantation HBV serologic result					HBV-related events after transplantation
HBsAg	Anti-HBs	Anti-HBc	Anti-HBe	Patients	HBV reactivation/total patients	Loss of antibody/total patients
Negative	Negative	Negative	Negative	45 (50.0)	1/45	1/45
Negative	Positive	Negative	Negative	15 (16.7)	-	8/15
Negative	Negative	Positive	Negative	3 (3.3)	2/3	1/3
Negative	Negative	Negative	Positive	1 (1.1)	-	-
Positive	Negative	Negative	Negative	3 (3.3)	-	-
Positive	Negative	Positive	Positive	3 (3.3)	-	-
Negative	Negative	Positive	Positive	5 (5.6)	-	-
Negative	Positive	Negative	Positive	3 (3.3)	-	-
Negative	Positive	Positive	Negative	6 (6.7)	-	4/6
Negative	Positive	Positive	Positive	6 (6.7)	-	-

HBV: Hepatitis B virus (HBV); HBsAg: HBV surface antigen; anti-HBs: Antibody to HBV surface antigen; anti-HBc: Antibody to HBV core antigen.

Table 3 Characteristics and serologic marker details of the patients with loss of antibody

Patients No.	Age (yr)	Gender	Antibody disappearance time (post-transplantation months)		Time of antibody reappearance (mo)	Disease
			Anti-HBs	Anti-HBc
#1	71	F	+6	-	+18	MM
#6	59	F	+6	-	-	MM
#8	50	M	+12	-	+18	MM
#10	48	F	+9	-	-	MM
#12	52	F	+24	+6	-	MM
#27	46	F	+1	-	+12	MM
#28	59	M	+1	-	+8	MM
#39	59	M	+1	-	-	MM
#40	30	M	-	+1	+6	NHL
#41	68	M	-	+3	-	MM
#43	16	F	+1	-	-	PNET
#48	56	F	+1	+1	+6 (anti-HBc)	MM
#55	64	M	+6	-	-	MM
#89	23	F	+3	-	-	HD

MM: Multiple myeloma; NHL: Non-Hodgkin’s lymphoma; PNET: Primitive neuroectodermal tumor.